Status: Recruiting
CD19 CAR-T Therapy for Refractory Pemphigus Vulgaris
This is an investigator-initiated, single-center, single-arm, open-label exploratory clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of autologous CD19 CAR-T cell therapy in patients with refractory pemphigus vulgaris.
Participants needed: 3
Trial details
Age: 18-70Biological sex: AllType: InterventionalSponsor: Jinbo ChenUpdated: Jul 2, 2026Locations: 1
Eligibility criteria
Ability to provide written informed consent. [+15]
Active uncontrolled infection at screening, requiring systemic antimicrobial the... [+12]